id	sid	tid	token	lemma	pos
cajgh-160	1	1	cajgh_template	cajgh_template	ADJ
cajgh-160	1	2	new	new	ADJ
cajgh-160	1	3	articles	article	NOUN
cajgh-160	1	4	in	in	ADP
cajgh-160	1	5	this	this	DET
cajgh-160	1	6	journal	journal	NOUN
cajgh-160	1	7	are	be	AUX
cajgh-160	1	8	licensed	license	VERB
cajgh-160	1	9	under	under	ADP
cajgh-160	1	10	a	a	DET
cajgh-160	1	11	creative	creative	ADJ
cajgh-160	1	12	commons	common	NOUN
cajgh-160	1	13	attribution	attribution	NOUN
cajgh-160	1	14	4.0	4.0	NUM
cajgh-160	1	15	united	unite	VERB
cajgh-160	1	16	states	states	PROPN
cajgh-160	1	17	license	license	NOUN
cajgh-160	1	18	.	.	PUNCT
cajgh-160	2	1	this	this	DET
cajgh-160	2	2	journal	journal	NOUN
cajgh-160	2	3	is	be	AUX
cajgh-160	2	4	published	publish	VERB
cajgh-160	2	5	by	by	ADP
cajgh-160	2	6	the	the	DET
cajgh-160	2	7	university	university	NOUN
cajgh-160	2	8	library	library	NOUN
cajgh-160	2	9	system	system	NOUN
cajgh-160	2	10	of	of	ADP
cajgh-160	2	11	the	the	DET
cajgh-160	2	12	university	university	PROPN
cajgh-160	2	13	of	of	ADP
cajgh-160	2	14	pittsburgh	pittsburgh	PROPN
cajgh-160	2	15	as	as	ADP
cajgh-160	2	16	part	part	NOUN
cajgh-160	2	17	of	of	ADP
cajgh-160	2	18	its	its	PRON
cajgh-160	2	19	d	d	NOUN
cajgh-160	2	20	-	-	PUNCT
cajgh-160	2	21	scribe	scribe	VERB
cajgh-160	2	22	digital	digital	ADJ
cajgh-160	2	23	publishing	publishing	NOUN
cajgh-160	2	24	program	program	NOUN
cajgh-160	2	25	and	and	CCONJ
cajgh-160	2	26	is	be	AUX
cajgh-160	2	27	cosponsored	cosponsor	VERB
cajgh-160	2	28	by	by	ADP
cajgh-160	2	29	the	the	DET
cajgh-160	2	30	university	university	PROPN
cajgh-160	2	31	of	of	ADP
cajgh-160	2	32	pittsburgh	pittsburgh	PROPN
cajgh-160	2	33	press	press	PROPN
cajgh-160	2	34	.	.	PUNCT
cajgh-160	3	1	association	association	NOUN
cajgh-160	3	2	between	between	ADP
cajgh-160	3	3	the	the	DET
cajgh-160	3	4	p2ry12	p2ry12	PROPN
cajgh-160	3	5	receptor	receptor	NOUN
cajgh-160	3	6	gene	gene	NOUN
cajgh-160	3	7	polymorphism	polymorphism	NOUN
cajgh-160	3	8	and	and	CCONJ
cajgh-160	3	9	aspirin	aspirin	NOUN
cajgh-160	3	10	resistance	resistance	NOUN
cajgh-160	3	11	in	in	ADP
cajgh-160	3	12	patients	patient	NOUN
cajgh-160	3	13	with	with	ADP
cajgh-160	3	14	coronary	coronary	ADJ
cajgh-160	3	15	artery	artery	NOUN
cajgh-160	3	16	disease	disease	NOUN
cajgh-160	3	17	ludmila	ludmila	PROPN
cajgh-160	3	18	karazhanova1	karazhanova1	PROPN
cajgh-160	3	19	,	,	PUNCT
cajgh-160	3	20	sholpan	sholpan	ADJ
cajgh-160	3	21	zhukusheva1	zhukusheva1	PROPN
cajgh-160	3	22	,	,	PUNCT
cajgh-160	3	23	ainur	ainur	NOUN
cajgh-160	3	24	akilzhanova2	akilzhanova2	NOUN
cajgh-160	4	1	1department	1department	NUM
cajgh-160	4	2	of	of	ADP
cajgh-160	4	3	internal	internal	ADJ
cajgh-160	4	4	medicine	medicine	NOUN
cajgh-160	4	5	,	,	PUNCT
cajgh-160	4	6	semey	semey	PROPN
cajgh-160	4	7	state	state	PROPN
cajgh-160	4	8	medical	medical	PROPN
cajgh-160	4	9	university	university	PROPN
cajgh-160	4	10	,	,	PUNCT
cajgh-160	4	11	astana	astana	PROPN
cajgh-160	4	12	,	,	PUNCT
cajgh-160	4	13	kazakhstan	kazakhstan	PROPN
cajgh-160	4	14	;	;	PUNCT
cajgh-160	4	15	2center	2center	NUM
cajgh-160	4	16	for	for	ADP
cajgh-160	4	17	life	life	NOUN
cajgh-160	4	18	sciences	science	NOUN
cajgh-160	4	19	,	,	PUNCT
cajgh-160	4	20	nazarbayev	nazarbayev	ADJ
cajgh-160	4	21	university	university	NOUN
cajgh-160	4	22	,	,	PUNCT
cajgh-160	4	23	astana	astana	PROPN
cajgh-160	4	24	,	,	PUNCT
cajgh-160	4	25	kazakhstan	kazakhstan	PROPN
cajgh-160	4	26	vol	vol	NOUN
cajgh-160	4	27	.	.	PROPN
cajgh-160	5	1	3	3	NUM
cajgh-160	5	2	,	,	PUNCT
cajgh-160	5	3	suppl	suppl	ADJ
cajgh-160	5	4	.	.	PUNCT
cajgh-160	6	1	(	(	PUNCT
cajgh-160	6	2	2014	2014	NUM
cajgh-160	6	3	)	)	PUNCT
cajgh-160	6	4	|	|	ADV
cajgh-160	6	5	issn	issn	VERB
cajgh-160	6	6	2166	2166	NUM
cajgh-160	6	7	-	-	SYM
cajgh-160	6	8	7403	7403	NUM
cajgh-160	6	9	(	(	PUNCT
cajgh-160	6	10	online	online	ADJ
cajgh-160	6	11	)	)	PUNCT
cajgh-160	6	12	doi	doi	NOUN
cajgh-160	6	13	10.5195	10.5195	NUM
cajgh-160	6	14	/	/	SYM
cajgh-160	6	15	cajgh.2014.160	cajgh.2014.160	NOUN
cajgh-160	6	16	|	|	NOUN
cajgh-160	6	17	http://cajgh.pitt.edu	http://cajgh.pitt.edu	NOUN
cajgh-160	6	18	http://www.library.pitt.edu/	http://www.library.pitt.edu/	PROPN
cajgh-160	6	19	http://www.pitt.edu/	http://www.pitt.edu/	NOUN
cajgh-160	6	20	http://www.library.pitt.edu/articles/digpubtype/index.html	http://www.library.pitt.edu/articles/digpubtype/index.html	PUNCT
cajgh-160	7	1	http://www.upress.pitt.edu/upressindex.aspx	http://www.upress.pitt.edu/upressindex.aspx	NUM
cajgh-160	7	2	http://creativecommons.org/licenses/by/3.0/us/	http://creativecommons.org/licenses/by/3.0/us/	NOUN
cajgh-160	7	3	karazhanova	karazhanova	VERB
cajgh-160	7	4	this	this	DET
cajgh-160	7	5	work	work	NOUN
cajgh-160	7	6	is	be	AUX
cajgh-160	7	7	licensed	license	VERB
cajgh-160	7	8	under	under	ADP
cajgh-160	7	9	a	a	DET
cajgh-160	7	10	creative	creative	ADJ
cajgh-160	7	11	commons	common	NOUN
cajgh-160	7	12	attribution	attribution	NOUN
cajgh-160	7	13	4.0	4.0	NUM
cajgh-160	7	14	united	unite	VERB
cajgh-160	7	15	states	states	PROPN
cajgh-160	7	16	license	license	NOUN
cajgh-160	7	17	.	.	PUNCT
cajgh-160	8	1	this	this	DET
cajgh-160	8	2	journal	journal	NOUN
cajgh-160	8	3	is	be	AUX
cajgh-160	8	4	published	publish	VERB
cajgh-160	8	5	by	by	ADP
cajgh-160	8	6	the	the	DET
cajgh-160	8	7	university	university	NOUN
cajgh-160	8	8	library	library	NOUN
cajgh-160	8	9	system	system	NOUN
cajgh-160	8	10	of	of	ADP
cajgh-160	8	11	the	the	DET
cajgh-160	8	12	university	university	PROPN
cajgh-160	8	13	of	of	ADP
cajgh-160	8	14	pittsburgh	pittsburgh	PROPN
cajgh-160	8	15	as	as	ADP
cajgh-160	8	16	part	part	NOUN
cajgh-160	8	17	of	of	ADP
cajgh-160	8	18	its	its	PRON
cajgh-160	8	19	d	d	NOUN
cajgh-160	8	20	-	-	PUNCT
cajgh-160	8	21	scribe	scribe	VERB
cajgh-160	8	22	digital	digital	ADJ
cajgh-160	8	23	publishing	publishing	NOUN
cajgh-160	8	24	program	program	NOUN
cajgh-160	8	25	and	and	CCONJ
cajgh-160	8	26	is	be	AUX
cajgh-160	8	27	cosponsored	cosponsor	VERB
cajgh-160	8	28	by	by	ADP
cajgh-160	8	29	the	the	DET
cajgh-160	8	30	university	university	PROPN
cajgh-160	8	31	of	of	ADP
cajgh-160	8	32	pittsburgh	pittsburgh	PROPN
cajgh-160	8	33	press	press	NOUN
cajgh-160	8	34	.	.	PUNCT
cajgh-160	9	1	central	central	ADJ
cajgh-160	9	2	asian	asian	ADJ
cajgh-160	9	3	journal	journal	NOUN
cajgh-160	9	4	of	of	ADP
cajgh-160	9	5	global	global	ADJ
cajgh-160	9	6	health	health	NOUN
cajgh-160	9	7	volume	volume	NOUN
cajgh-160	9	8	3	3	NUM
cajgh-160	9	9	,	,	PUNCT
cajgh-160	9	10	suppl	suppl	ADJ
cajgh-160	9	11	.	.	PUNCT
cajgh-160	10	1	(	(	PUNCT
cajgh-160	10	2	2014	2014	NUM
cajgh-160	10	3	)	)	PUNCT
cajgh-160	10	4	|	|	ADV
cajgh-160	10	5	issn	issn	VERB
cajgh-160	10	6	2166	2166	NUM
cajgh-160	10	7	-	-	SYM
cajgh-160	10	8	7403	7403	NUM
cajgh-160	10	9	(	(	PUNCT
cajgh-160	10	10	online	online	ADJ
cajgh-160	10	11	)	)	PUNCT
cajgh-160	10	12	|	|	ADV
cajgh-160	10	13	doi	doi	X
cajgh-160	10	14	10.5195	10.5195	NUM
cajgh-160	10	15	/	/	SYM
cajgh-160	10	16	cajgh.2014.160	cajgh.2014.160	NOUN
cajgh-160	10	17	|	|	NOUN
cajgh-160	10	18	http://cajgh.pitt.edu	http://cajgh.pitt.edu	NOUN
cajgh-160	10	19	abstract	abstract	ADJ
cajgh-160	10	20	introduction	introduction	NOUN
cajgh-160	10	21	.	.	PUNCT
cajgh-160	11	1	platelet	platelet	NOUN
cajgh-160	11	2	activation	activation	NOUN
cajgh-160	11	3	and	and	CCONJ
cajgh-160	11	4	aggregation	aggregation	NOUN
cajgh-160	11	5	are	be	AUX
cajgh-160	11	6	key	key	ADJ
cajgh-160	11	7	elements	element	NOUN
cajgh-160	11	8	in	in	ADP
cajgh-160	11	9	the	the	DET
cajgh-160	11	10	development	development	NOUN
cajgh-160	11	11	of	of	ADP
cajgh-160	11	12	coronary	coronary	ADJ
cajgh-160	11	13	atherosclerosis	atherosclerosis	NOUN
cajgh-160	11	14	.	.	PUNCT
cajgh-160	12	1	recent	recent	ADJ
cajgh-160	12	2	studies	study	NOUN
cajgh-160	12	3	have	have	AUX
cajgh-160	12	4	shown	show	VERB
cajgh-160	12	5	that	that	SCONJ
cajgh-160	12	6	the	the	DET
cajgh-160	12	7	two	two	NUM
cajgh-160	12	8	polymorphisms	polymorphism	NOUN
cajgh-160	12	9	of	of	ADP
cajgh-160	12	10	platelet	platelet	NOUN
cajgh-160	12	11	adp	adp	PROPN
cajgh-160	12	12	receptor	receptor	NOUN
cajgh-160	12	13	p2ry12	p2ry12	PROPN
cajgh-160	12	14	(	(	PUNCT
cajgh-160	12	15	haplotypes	haplotype	NOUN
cajgh-160	12	16	h2	h2	PROPN
cajgh-160	12	17	and	and	CCONJ
cajgh-160	12	18	34	34	NUM
cajgh-160	12	19	t	t	NOUN
cajgh-160	12	20	)	)	PUNCT
cajgh-160	12	21	are	be	AUX
cajgh-160	12	22	associated	associate	VERB
cajgh-160	12	23	with	with	ADP
cajgh-160	12	24	increased	increase	VERB
cajgh-160	12	25	platelet	platelet	NOUN
cajgh-160	12	26	aggregation	aggregation	NOUN
cajgh-160	12	27	and	and	CCONJ
cajgh-160	12	28	atherothrombotic	atherothrombotic	ADJ
cajgh-160	12	29	risk	risk	NOUN
cajgh-160	12	30	.	.	PUNCT
cajgh-160	13	1	it	it	PRON
cajgh-160	13	2	was	be	AUX
cajgh-160	13	3	shown	show	VERB
cajgh-160	13	4	that	that	SCONJ
cajgh-160	13	5	these	these	DET
cajgh-160	13	6	polymorphisms	polymorphism	NOUN
cajgh-160	13	7	promote	promote	VERB
cajgh-160	13	8	reduced	reduced	ADJ
cajgh-160	13	9	body	body	NOUN
cajgh-160	13	10	response	response	NOUN
cajgh-160	13	11	to	to	PART
cajgh-160	13	12	antiplatelet	antiplatelet	VERB
cajgh-160	13	13	therapy	therapy	NOUN
cajgh-160	13	14	.	.	PUNCT
cajgh-160	14	1	aim	aim	VERB
cajgh-160	14	2	.	.	PUNCT
cajgh-160	15	1	we	we	PRON
cajgh-160	15	2	investigated	investigate	VERB
cajgh-160	15	3	the	the	DET
cajgh-160	15	4	association	association	NOUN
cajgh-160	15	5	of	of	ADP
cajgh-160	15	6	p2ry12	p2ry12	PROPN
cajgh-160	15	7	gene	gene	NOUN
cajgh-160	15	8	polymorphisms	polymorphism	NOUN
cajgh-160	15	9	with	with	ADP
cajgh-160	15	10	aspirin	aspirin	NOUN
cajgh-160	15	11	resistance	resistance	NOUN
cajgh-160	15	12	in	in	ADP
cajgh-160	15	13	patients	patient	NOUN
cajgh-160	15	14	with	with	ADP
cajgh-160	15	15	coronary	coronary	ADJ
cajgh-160	15	16	artery	artery	NOUN
cajgh-160	15	17	disease	disease	NOUN
cajgh-160	15	18	(	(	PUNCT
cajgh-160	15	19	cad	cad	NOUN
cajgh-160	15	20	)	)	PUNCT
cajgh-160	15	21	.	.	PUNCT
cajgh-160	16	1	methods	method	NOUN
cajgh-160	16	2	.	.	PUNCT
cajgh-160	17	1	this	this	DET
cajgh-160	17	2	case	case	NOUN
cajgh-160	17	3	-	-	PUNCT
cajgh-160	17	4	control	control	NOUN
cajgh-160	17	5	study	study	NOUN
cajgh-160	17	6	included	include	VERB
cajgh-160	17	7	100	100	NUM
cajgh-160	17	8	cases	case	NOUN
cajgh-160	17	9	with	with	ADP
cajgh-160	17	10	cad	cad	PROPN
cajgh-160	17	11	(	(	PUNCT
cajgh-160	17	12	mean	mean	VERB
cajgh-160	17	13	age	age	NOUN
cajgh-160	17	14	57.6	57.6	NUM
cajgh-160	17	15	±	±	NUM
cajgh-160	17	16	2.8	2.8	NUM
cajgh-160	17	17	years	year	NOUN
cajgh-160	17	18	)	)	PUNCT
cajgh-160	17	19	treated	treat	VERB
cajgh-160	17	20	in	in	ADP
cajgh-160	17	21	the	the	DET
cajgh-160	17	22	cardiology	cardiology	NOUN
cajgh-160	17	23	department	department	NOUN
cajgh-160	17	24	of	of	ADP
cajgh-160	17	25	the	the	DET
cajgh-160	17	26	city	city	PROPN
cajgh-160	17	27	hospital	hospital	PROPN
cajgh-160	17	28	semey	semey	PROPN
cajgh-160	17	29	,	,	PUNCT
cajgh-160	17	30	kazakhstan	kazakhstan	PROPN
cajgh-160	17	31	,	,	PUNCT
cajgh-160	17	32	90	90	NUM
cajgh-160	17	33	of	of	ADP
cajgh-160	17	34	whom	whom	PRON
cajgh-160	17	35	suffered	suffer	VERB
cajgh-160	17	36	from	from	ADP
cajgh-160	17	37	myocardial	myocardial	ADJ
cajgh-160	17	38	infarction	infarction	NOUN
cajgh-160	17	39	.	.	PUNCT
cajgh-160	18	1	the	the	DET
cajgh-160	18	2	control	control	PROPN
cajgh-160	18	3	group	group	NOUN
cajgh-160	18	4	(	(	PUNCT
cajgh-160	18	5	n	n	NOUN
cajgh-160	18	6	=	=	SYM
cajgh-160	18	7	100	100	NUM
cajgh-160	18	8	)	)	PUNCT
cajgh-160	18	9	were	be	AUX
cajgh-160	18	10	healthy	healthy	ADJ
cajgh-160	18	11	people	people	NOUN
cajgh-160	18	12	without	without	ADP
cajgh-160	18	13	a	a	DET
cajgh-160	18	14	history	history	NOUN
cajgh-160	18	15	of	of	ADP
cajgh-160	18	16	cad	cad	PROPN
cajgh-160	18	17	,	,	PUNCT
cajgh-160	18	18	matched	match	VERB
cajgh-160	18	19	on	on	ADP
cajgh-160	18	20	sex	sex	NOUN
cajgh-160	18	21	and	and	CCONJ
cajgh-160	18	22	age	age	NOUN
cajgh-160	18	23	.	.	PUNCT
cajgh-160	19	1	genotyping	genotyping	NOUN
cajgh-160	19	2	of	of	ADP
cajgh-160	19	3	polymorphisms	polymorphism	NOUN
cajgh-160	19	4	h1	h1	PROPN
cajgh-160	19	5	/	/	SYM
cajgh-160	19	6	h2	h2	PROPN
cajgh-160	19	7	in	in	ADP
cajgh-160	19	8	p2ry12	p2ry12	DET
cajgh-160	19	9	gene	gene	NOUN
cajgh-160	19	10	was	be	AUX
cajgh-160	19	11	performed	perform	VERB
cajgh-160	19	12	by	by	ADP
cajgh-160	19	13	pcr	pcr	PROPN
cajgh-160	19	14	.	.	PUNCT
cajgh-160	20	1	statistical	statistical	ADJ
cajgh-160	20	2	analysis	analysis	NOUN
cajgh-160	20	3	was	be	AUX
cajgh-160	20	4	performed	perform	VERB
cajgh-160	20	5	using	use	VERB
cajgh-160	20	6	spss	spss	PROPN
cajgh-160	20	7	v.19.0	v.19.0	PROPN
cajgh-160	20	8	.	.	PROPN
cajgh-160	20	9	results	result	NOUN
cajgh-160	20	10	.	.	PUNCT
cajgh-160	21	1	the	the	DET
cajgh-160	21	2	distribution	distribution	NOUN
cajgh-160	21	3	of	of	ADP
cajgh-160	21	4	h1	h1	PROPN
cajgh-160	21	5	/	/	SYM
cajgh-160	21	6	h2	h2	NOUN
cajgh-160	21	7	genotypes	genotype	NOUN
cajgh-160	21	8	p2ry12	p2ry12	PRON
cajgh-160	21	9	was	be	AUX
cajgh-160	21	10	42	42	NUM
cajgh-160	21	11	%	%	NOUN
cajgh-160	21	12	,	,	PUNCT
cajgh-160	21	13	34	34	NUM
cajgh-160	21	14	%	%	NOUN
cajgh-160	21	15	,	,	PUNCT
cajgh-160	21	16	and	and	CCONJ
cajgh-160	21	17	24	24	NUM
cajgh-160	21	18	%	%	NOUN
cajgh-160	21	19	,	,	PUNCT
cajgh-160	21	20	respectively	respectively	ADV
cajgh-160	21	21	,	,	PUNCT
cajgh-160	21	22	in	in	ADP
cajgh-160	21	23	cases	case	NOUN
cajgh-160	21	24	and	and	CCONJ
cajgh-160	21	25	42	42	NUM
cajgh-160	21	26	%	%	NOUN
cajgh-160	21	27	,	,	PUNCT
cajgh-160	21	28	58	58	NUM
cajgh-160	21	29	%	%	NOUN
cajgh-160	21	30	,	,	PUNCT
cajgh-160	21	31	and	and	CCONJ
cajgh-160	21	32	0	0	NUM
cajgh-160	21	33	%	%	NOUN
cajgh-160	21	34	,	,	PUNCT
cajgh-160	21	35	respectively	respectively	ADV
cajgh-160	21	36	,	,	PUNCT
cajgh-160	21	37	in	in	ADP
cajgh-160	21	38	controls	control	NOUN
cajgh-160	21	39	.	.	PUNCT
cajgh-160	22	1	all	all	DET
cajgh-160	22	2	allele	allele	NOUN
cajgh-160	22	3	frequencies	frequency	NOUN
cajgh-160	22	4	were	be	AUX
cajgh-160	22	5	consistent	consistent	ADJ
cajgh-160	22	6	with	with	ADP
cajgh-160	22	7	the	the	DET
cajgh-160	22	8	hardy	hardy	PROPN
cajgh-160	22	9	weinberg	weinberg	PROPN
cajgh-160	22	10	equilibrium	equilibrium	NOUN
cajgh-160	22	11	(	(	PUNCT
cajgh-160	22	12	p	p	X
cajgh-160	22	13	=	=	SYM
cajgh-160	22	14	0.0036	0.0036	NUM
cajgh-160	22	15	and	and	CCONJ
cajgh-160	22	16	p	p	NOUN
cajgh-160	22	17	=	=	SYM
cajgh-160	22	18	0.0001	0.0001	NUM
cajgh-160	22	19	in	in	ADP
cajgh-160	22	20	cases	case	NOUN
cajgh-160	22	21	and	and	CCONJ
cajgh-160	22	22	controls	control	NOUN
cajgh-160	22	23	,	,	PUNCT
cajgh-160	22	24	respectively	respectively	ADV
cajgh-160	22	25	)	)	PUNCT
cajgh-160	22	26	.	.	PUNCT
cajgh-160	23	1	genotype	genotype	NOUN
cajgh-160	23	2	h2	h2	PROPN
cajgh-160	23	3	was	be	AUX
cajgh-160	23	4	associated	associate	VERB
cajgh-160	23	5	with	with	ADP
cajgh-160	23	6	risk	risk	NOUN
cajgh-160	23	7	of	of	ADP
cajgh-160	23	8	cad	cad	PROPN
cajgh-160	23	9	with	with	ADP
cajgh-160	23	10	aspirin	aspirin	NOUN
cajgh-160	23	11	resistance	resistance	NOUN
cajgh-160	23	12	(	(	PUNCT
cajgh-160	23	13	co	co	ADJ
cajgh-160	23	14	-	-	ADJ
cajgh-160	23	15	dominant	dominant	ADJ
cajgh-160	23	16	model	model	NOUN
cajgh-160	23	17	:	:	PUNCT
cajgh-160	23	18	or	or	CCONJ
cajgh-160	23	19	=	=	SYM
cajgh-160	23	20	3.75	3.75	NUM
cajgh-160	23	21	,	,	PUNCT
cajgh-160	23	22	95	95	NUM
cajgh-160	23	23	%	%	NOUN
cajgh-160	23	24	ci	ci	NOUN
cajgh-160	23	25	0.14	0.14	NUM
cajgh-160	23	26	99.88	99.88	NUM
cajgh-160	23	27	,	,	PUNCT
cajgh-160	23	28	p	p	NOUN
cajgh-160	23	29	=	=	NOUN
cajgh-160	23	30	0.05	0.05	NUM
cajgh-160	23	31	and	and	CCONJ
cajgh-160	23	32	dominant	dominant	ADJ
cajgh-160	23	33	model	model	NOUN
cajgh-160	23	34	:	:	PUNCT
cajgh-160	23	35	or	or	CCONJ
cajgh-160	23	36	=	=	SYM
cajgh-160	23	37	2.78	2.78	NUM
cajgh-160	23	38	,	,	PUNCT
cajgh-160	23	39	95	95	NUM
cajgh-160	23	40	%	%	NOUN
cajgh-160	23	41	ci	ci	NOUN
cajgh-160	23	42	0.11	0.11	NUM
cajgh-160	23	43	70.93	70.93	NUM
cajgh-160	23	44	,	,	PUNCT
cajgh-160	23	45	p	p	X
cajgh-160	23	46	=	=	NOUN
cajgh-160	23	47	0.05	0.05	NUM
cajgh-160	23	48	)	)	PUNCT
cajgh-160	23	49	.	.	PUNCT
cajgh-160	24	1	we	we	PRON
cajgh-160	24	2	found	find	VERB
cajgh-160	24	3	significant	significant	ADJ
cajgh-160	24	4	differences	difference	NOUN
cajgh-160	24	5	in	in	ADP
cajgh-160	24	6	the	the	DET
cajgh-160	24	7	distribution	distribution	NOUN
cajgh-160	24	8	of	of	ADP
cajgh-160	24	9	the	the	DET
cajgh-160	24	10	mutant	mutant	ADJ
cajgh-160	24	11	genotype	genotype	NOUN
cajgh-160	24	12	h2	h2	NOUN
cajgh-160	24	13	between	between	ADP
cajgh-160	24	14	cad	cad	PROPN
cajgh-160	24	15	patients	patient	NOUN
cajgh-160	24	16	with	with	ADP
cajgh-160	24	17	aspirin	aspirin	NOUN
cajgh-160	24	18	resistance	resistance	NOUN
cajgh-160	24	19	and	and	CCONJ
cajgh-160	24	20	healthy	healthy	ADJ
cajgh-160	24	21	controls	control	NOUN
cajgh-160	24	22	(	(	PUNCT
cajgh-160	24	23	χ2	χ2	NOUN
cajgh-160	24	24	=	=	PUNCT
cajgh-160	24	25	30.3	30.3	NUM
cajgh-160	24	26	,	,	PUNCT
cajgh-160	24	27	p	p	X
cajgh-160	24	28	<	<	X
cajgh-160	24	29	0.05	0.05	NUM
cajgh-160	24	30	)	)	PUNCT
cajgh-160	24	31	.	.	PUNCT
cajgh-160	25	1	conclusion	conclusion	NOUN
cajgh-160	25	2	.	.	PUNCT
cajgh-160	26	1	we	we	PRON
cajgh-160	26	2	found	find	VERB
cajgh-160	26	3	an	an	DET
cajgh-160	26	4	association	association	NOUN
cajgh-160	26	5	of	of	ADP
cajgh-160	26	6	h2	h2	PROPN
cajgh-160	26	7	haplotype	haplotype	NOUN
cajgh-160	26	8	in	in	ADP
cajgh-160	26	9	p2ry12	p2ry12	PROPN
cajgh-160	26	10	gene	gene	NOUN
cajgh-160	26	11	with	with	ADP
cajgh-160	26	12	aspirin	aspirin	NOUN
cajgh-160	26	13	resistance	resistance	NOUN
cajgh-160	26	14	in	in	ADP
cajgh-160	26	15	patients	patient	NOUN
cajgh-160	26	16	with	with	ADP
cajgh-160	26	17	cad	cad	PROPN
cajgh-160	26	18	.	.	PUNCT
cajgh-160	27	1	however	however	ADV
cajgh-160	27	2	,	,	PUNCT
cajgh-160	27	3	in	in	ADP
cajgh-160	27	4	order	order	NOUN
cajgh-160	27	5	to	to	PART
cajgh-160	27	6	obtain	obtain	VERB
cajgh-160	27	7	definitive	definitive	ADJ
cajgh-160	27	8	conclusions	conclusion	NOUN
cajgh-160	27	9	about	about	ADP
cajgh-160	27	10	the	the	DET
cajgh-160	27	11	role	role	NOUN
cajgh-160	27	12	of	of	ADP
cajgh-160	27	13	genetic	genetic	ADJ
cajgh-160	27	14	variants	variant	NOUN
cajgh-160	27	15	with	with	ADP
cajgh-160	27	16	the	the	DET
cajgh-160	27	17	development	development	NOUN
cajgh-160	27	18	of	of	ADP
cajgh-160	27	19	aspirin	aspirin	NOUN
cajgh-160	27	20	resistance	resistance	NOUN
cajgh-160	27	21	in	in	ADP
cajgh-160	27	22	patients	patient	NOUN
cajgh-160	27	23	with	with	ADP
cajgh-160	27	24	cad	cad	PROPN
cajgh-160	27	25	,	,	PUNCT
cajgh-160	27	26	there	there	PRON
cajgh-160	27	27	is	be	VERB
cajgh-160	27	28	a	a	DET
cajgh-160	27	29	need	need	NOUN
cajgh-160	27	30	for	for	ADP
cajgh-160	27	31	further	further	ADJ
cajgh-160	27	32	research	research	NOUN
cajgh-160	27	33	with	with	ADP
cajgh-160	27	34	a	a	DET
cajgh-160	27	35	larger	large	ADJ
cajgh-160	27	36	sample	sample	NOUN
cajgh-160	27	37	size	size	NOUN
cajgh-160	27	38	as	as	ADV
cajgh-160	27	39	well	well	ADV
cajgh-160	27	40	as	as	ADP
cajgh-160	27	41	the	the	DET
cajgh-160	27	42	use	use	NOUN
cajgh-160	27	43	of	of	ADP
cajgh-160	27	44	selective	selective	ADJ
cajgh-160	27	45	thromboxane	thromboxane	NOUN
cajgh-160	27	46	receptor	receptor	NOUN
cajgh-160	27	47	antagonists	antagonist	NOUN
cajgh-160	27	48	for	for	ADP
cajgh-160	27	49	studying	study	VERB
cajgh-160	27	50	functional	functional	ADJ
cajgh-160	27	51	effects	effect	NOUN
cajgh-160	27	52	of	of	ADP
cajgh-160	27	53	genetic	genetic	ADJ
cajgh-160	27	54	variants	variant	NOUN
cajgh-160	27	55	.	.	PUNCT
cajgh-160	28	1	keywords	keyword	NOUN
cajgh-160	28	2	:	:	PUNCT
cajgh-160	28	3	coronary	coronary	ADJ
cajgh-160	28	4	artery	artery	NOUN
cajgh-160	28	5	disease	disease	NOUN
cajgh-160	28	6	,	,	PUNCT
cajgh-160	28	7	aspirin	aspirin	NOUN
cajgh-160	28	8	resistance	resistance	NOUN
cajgh-160	28	9	,	,	PUNCT
cajgh-160	28	10	gene	gene	NOUN
cajgh-160	28	11	polymorphism	polymorphism	NOUN
cajgh-160	28	12	http://www.library.pitt.edu/	http://www.library.pitt.edu/	PROPN
cajgh-160	28	13	http://www.pitt.edu/	http://www.pitt.edu/	NOUN
cajgh-160	28	14	http://www.library.pitt.edu/articles/digpubtype/index.html	http://www.library.pitt.edu/articles/digpubtype/index.html	PUNCT
cajgh-160	29	1	http://www.upress.pitt.edu/upressindex.aspx	http://www.upress.pitt.edu/upressindex.aspx	X